The Pharma and Biotech Patent Litigation Summit returned to Anantara Grand Hotel in January for 3 days practical discussion surrounding the leading patent litigation topics in Europe, with a compare and contrast method with jurisdictions further afield. Our internationally recognised summit provided our delegates with the necessary practical tools to both defend patent litigation challenges for their pharma and biotech product, whilst also maximising their litigation strategy to allow for successful IP protection. With the central case law and regulatory updates, this event was a must-attend for anyone with a focus on the European market and working within life science IP.
This year’s summit hosted a cross-industry UPC Litigation Forum 2024 as a one-day meeting on 22nd January. This event hosted the leading litigators and patent attorneys, in-house counsel and judges for a practical review of the early-stage experience of the UPC. At this event, you will network with leading figures in the industry and gain unique insights on the latest regulatory changes and case-law updates.
Highlights For This Year Included:
Form a holistic and practical UPC litigation strategy with a cross-industry case law review, a mock trial alongside leading judges and litigators and a pharma and biotech UPC strategy panel.
Update your pharma and biotech patent litigation strategy with the latest regulatory developments and case law regarding the doctrine of equivalents, second medical use, preliminary injunctions and divisional patent practice.
Develop a transatlantic understanding of patentability concerns with an Amgen vs Sanofi case law review and an industry-panel concerning the G2/21 EPO Board of Appeals decision.
Form a global understanding of the patent litigation ecosphere with a panel of judges from the UK, EPO, USA and the UPC.
